Glaucoma is a global leading cause of blindness. This work focuses on use of biodegradable, environmentally responsive,therapeutically enhanced biomaterials for injectable ocular drug delivery. Single application of drug-loaded gel depots/nanocarriers is advantageous to extend release profile, alleviate postoperative complication,facilitate tissue rehabilitation during disease treatment.

For glaucoma treatment, current modalities including eye drop instillationsurgical intervention are limited by relatively low ocular drug bioavailabilitysevere inflammatory tissue response. Intracameral administration of newly developed gel depots/nanocarriers can significantly extend antiglaucoma drug releaseenhance retinal cytoprotection, thereby improving therapeutic performance.

To meet clinical demands for achieving minimally invasive drug delivery, an injectable biomaterial carrier is developed as a long-acting release platform for intracameral administration of antiglaucoma medicationssimultaneous alleviation of disease symptoms. It will be beneficial to not only glaucomaother ocular complications, but also economic potential of healthcare industry/marketing.